An Australian biotech company is launching a novel attack on Alzheimer's disease. Rather than following the traditional treatment paths, it is taking a new route.
This month the first of 174 patients on an international trial will begin taking a drug to lessen the level of the stress hormone, cortisol, in the brain.
Loading...
Jill Margo was a senior writer at The Australian Financial Review.
